Breaking News

Perspective Therapeutics, PharmaLogic Partner to Develop Theranostics for Cancer

PharmaLogic will produce and supply doses of VMT-01 and VMT-α-NET for use in Perspective's early-stage clinical trials.

PharmaLogic Holdings Corp., a contract development and manufacturing organization (CDMO) and radiopharmaceutical manufacturer, entered into a master services agreement with Viewpoint Molecular Targeting, Inc., a wholly owned subsidiary of Perspective Therapeutics, Inc., for the development and production of theranostic candidates VMT-01 and VMT-α-NET. The radiopharmaceuticals are currently in development for the diagnosis and treatment of metastatic melanoma and neuroendocrine tumors (NETs), ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters